Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer.

PURPOSE The prognostic and predictive value of epidermal growth factor receptor (EGFR) expression was evaluated in patients with recurrent breast cancer. EXPERIMENTAL DESIGN The immunohistochemical expression of EGFR was analyzed in 241 patients with recurrent breast cancer. RESULTS EGFR expression was positive in 87 of 241 (36%) patients with recurrent breast cancer, whereas the EGFR expression inversely correlated with the estrogen receptor (ER) status. The patients with positive EGFR expression had a significantly worse postrelapse survival than those with a negative EGFR expression, whereas EGFR expression also had a postrelapse prognostic significance in patients with a positive ER status. A multivariate analysis indicated EGFR expression to be an independently significant factor for postrelapse survival, whereas a multivariate analysis in which the ER status was added to variables indicated that ER status but not EGFR expression to be an independently significant factor. There was a significant difference between positive and negative EGFR expression in the treatment response of 82 patients who received hormonal therapies and 374 patients who received chemotherapies, whereas a multivariate analysis indicated the responses to the first-line treatment and EGFR expression to be independently significant factors for postrelapse survival. CONCLUSIONS EGFR expression had prognostic significance in recurrent breast cancer, whereas its prognostic value was not independent of the ER status. In addition, the EGFR expression was suggested to be related to the responses to hormonal therapy and chemotherapy, whereas the EGFR expression had an additional prognostic value that was independent of the treatment response.

[1]  S. Tsutsui,et al.  Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer , 2002, Breast cancer.

[2]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[3]  S. Tsutsui,et al.  Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer , 2004, Breast Cancer Research and Treatment.

[4]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[5]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[6]  I. Ellis,et al.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.

[7]  R. Yarden,et al.  Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. , 1996, Endocrinology.

[8]  S. Bates,et al.  Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor , 1995, Molecular and Cellular Endocrinology.

[9]  J. Farndon,et al.  Synthetic oligonucleotides as therapeutic agents. , 1991, British Journal of Cancer.

[10]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[11]  J. Foekens,et al.  Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. , 1992, Cancer research.

[12]  R. Nicholson,et al.  Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. , 1994, British Journal of Cancer.

[13]  I. Ellis,et al.  Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.

[14]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[15]  E. Gelmann,et al.  Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. , 1987, Molecular endocrinology.

[16]  J. Farndon,et al.  Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. , 1989, Journal of steroid biochemistry.

[17]  R. Rubens,et al.  Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. , 1981, European journal of cancer.

[18]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[19]  J. Downward,et al.  Autophosphorylation sites on the epidermal growth factor receptor , 1984, Nature.

[20]  S. Fox,et al.  The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients , 2004, Breast Cancer Research and Treatment.

[21]  A. Ruíz,et al.  Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[22]  J. Gee,et al.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer , 2000, British Journal of Cancer.

[23]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[24]  X. F. Dong,et al.  Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. , 1989, Biochemical and biophysical research communications.

[25]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[26]  G M Clark,et al.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Mendelsohn,et al.  Epidermal growth factor receptor family and chemosensitization. , 1997, Journal of the National Cancer Institute.

[28]  D. Horsfall,et al.  Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer , 1996, International journal of cancer.

[29]  M. Millward,et al.  Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer , 1991, The Lancet.

[30]  K. Korach,et al.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.

[31]  I. Ellis,et al.  Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. , 1993, European journal of cancer.

[32]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .